NCT02082977View on ClinicalTrials.gov

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma

PHASE1TerminatedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

April 24, 2014

Primary Completion Date

June 20, 2017

Study Completion Date

June 20, 2017

Conditions
CancerNeoplasms
Interventions
DRUG

GSK2816126

GSK2816126 will be supplied as a solution containing 15 milligram per milliliter (mg/mL) GSK2816126 in water for injection.

Trial Locations (5)

10021

GSK Investigational Site, New York

60611

GSK Investigational Site, Chicago

94805

GSK Investigational Site, Villejuif

SM2 5PT

GSK Investigational Site, Sutton

SO16 6YD

GSK Investigational Site, Southampton

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02082977 - A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma | Biotech Hunter | Biotech Hunter